HEPATITIS C TREATMENT MEDICATION
Most pharmaceutical companies offer help to patients who cannot afford the medications needed to treat Hepatitis C. You should work with your doctor to select and contact programs for assistance. In fact, your doctor may have the forms you need to submit to get medications at reduced cost or no cost. Your doctor may help you apply for assistance. Some pharmaceutical companies also offer programs to help patients learn more about Hepatitis C and manage treatment side effects. Check those out too.
Gilead-Harvoni (Sofosbuvuir/Valpatasvir/Voxilaprevir)
FDA Approved in October 2014
HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, HARVONI is used with ribavirin.
Epclusa (Sofosbuvuir/Valpatasvir)
FDA Approved in June 28th, 2016
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:
- without cirrhosis or with compensated cirrhosis
- with advanced cirrhosis (decompensated) in combination with ribavirin
EPCLUSA contains the two medicines: sofosbuvir and velpatasvir.
It is not known if EPCLUSA is safe and effective in children under 18 years of age.
Generic Medication
Gilead released generics for two of their most popular brand medications: Harvoni and Epclusa. These are the only generic medications approved so far to treat hepatitis C. Generic medications are instrumental in providing treatment options for those struggling to pay for their hepatitis C medications. Harvoni’s generic is ledipasvir/sofosbuvir and Epclusa’s generic is velpatasvir/sofosbuvir. Both of these generics are exact replicas of their brand-name counterparts, with the same forms and strengths. Harvoni’s generic is available as a tablet with a strength of 90 mg/400 mg, and Epclusas’s generic is available as a tablet with a strength of 400 mg/100 mg.
Sovaldi (Sofosbuvir)
FDA Approved in December 6, 2013
SOVALDI (sofosbuvir) is indicated for the treatment of chronic HCV infection without cirrhosis or with compensated cirrhosis in adults with genotype 1, 2, 3 or 4 (as a component of a combination antiviral treatment regimen) and in pediatric patients ≥3 years with genotype 2 or 3 (in combination with ribavirin).
Vosevi
FDA Approved in July 18. 2017
VOSEVI is indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have:
- Genotype 1, 2, 3, 4, 5 or 6 and were previously treated with an NS5A inhibitor.
- Genotype 1a or 3 and were previously treated with sofosbuvir without an NS5A inhibitor; additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5 or 6 infection in this population.
FDA Approved in October 2014
HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, HARVONI is used with ribavirin.
Epclusa (Sofosbuvuir/Valpatasvir)
FDA Approved in June 28th, 2016
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:
- without cirrhosis or with compensated cirrhosis
- with advanced cirrhosis (decompensated) in combination with ribavirin
EPCLUSA contains the two medicines: sofosbuvir and velpatasvir.
It is not known if EPCLUSA is safe and effective in children under 18 years of age.
Generic Medication
Gilead released generics for two of their most popular brand medications: Harvoni and Epclusa. These are the only generic medications approved so far to treat hepatitis C. Generic medications are instrumental in providing treatment options for those struggling to pay for their hepatitis C medications. Harvoni’s generic is ledipasvir/sofosbuvir and Epclusa’s generic is velpatasvir/sofosbuvir. Both of these generics are exact replicas of their brand-name counterparts, with the same forms and strengths. Harvoni’s generic is available as a tablet with a strength of 90 mg/400 mg, and Epclusas’s generic is available as a tablet with a strength of 400 mg/100 mg.
Sovaldi (Sofosbuvir)
FDA Approved in December 6, 2013
SOVALDI (sofosbuvir) is indicated for the treatment of chronic HCV infection without cirrhosis or with compensated cirrhosis in adults with genotype 1, 2, 3 or 4 (as a component of a combination antiviral treatment regimen) and in pediatric patients ≥3 years with genotype 2 or 3 (in combination with ribavirin).
Vosevi
FDA Approved in July 18. 2017
VOSEVI is indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have:
- Genotype 1, 2, 3, 4, 5 or 6 and were previously treated with an NS5A inhibitor.
- Genotype 1a or 3 and were previously treated with sofosbuvir without an NS5A inhibitor; additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5 or 6 infection in this population.
Gilead Patient Assistance
U.S. Patient Support Program
Gilead - Website links and resources
http://www.harvoni.com/
http://www.gilead.com/responsibility/us-patient-access/support path for sovaldi and harvoni
http://www.mysupportpath.com/
https://www.harvoni.com/support
U.S. Patient Support Program
- Gilead is committed to ensuring that people with hepatitis C can access Sovaldi and has launched Support Path(tm) (www.MySupportPath.com) to provide assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program consists of an integrated offering of support services for patients and providers, including:
- To assist eligible hepatitis C patients in the United States with access to Harvoni, Gilead has added the medicine to its Support Path™ (www.MySupportPath.com) program. The program consists of an integrated offering of support services for patients and providers, among them:
- Call center staffed with associates trained to help patients and their providers with insurance-related needs.
- Education and support, including a 24/7 nursing support service line.
- The Co-pay Coupon Program, which covers Epclusa, Harvoni, Vosevi, Sovaldi, & the Generic Medications, provides co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs. Most patients will pay no more than $5 per co-pay.
Gilead - Website links and resources
http://www.harvoni.com/
http://www.gilead.com/responsibility/us-patient-access/support path for sovaldi and harvoni
http://www.mysupportpath.com/
https://www.harvoni.com/support
AbbVie - MAVYRET (Glecaprevir/Pibrentasvir)
FDA Approved August 3rd 2017 For the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both AbbVie Patient Assistance Program www.mavyret.com/patient-support CALL TO LEARN MORE: 877-628-9738 |